George A. Scangos, Ph.D. was appointed Chief Executive Officer and a member of the Board of Directors in June 2010. He joined Biogen Idec from Exelixis, Inc., where he served as President and CEO and a director since October 1996. From 1987 to 1996, Dr. Scangos held various positions at Bayer, Inc, including SVP of R&D, and President of Bayer Biotechnology, where he was responsible for research, business development, process development, manufacturing, engineering and quality assurance of Bayer’s recombinant products. Before joining Bayer in 1987, Dr. Scangos was Professor of Biology at Johns Hopkins University. Dr. Scangos has served on a variety of company and non-profit boards, and currently serves on the Board of Directors of Exelixis, the Board of Advisors for the UC Davis School of Medicine, the Board of Trustees for the Boston Museum of Science, and the Board of Directors of the Biomedical Sciences Training Program, which is focused on helping minority and disadvantaged students to have careers in science and medicine. Dr. Scangos received a B.A. In Biology from Cornell University, and a Ph.D. From the University of Massachusetts. He was a Jane Coffin Childs Post-Doctoral Fellow in the laboratory of Dr. Frank Ruddle at Yale University.
Susan H. Alexander is our Executive Vice President, General Counsel and Corporate Secretary and has served in these positions since January 2006. Prior to that, Ms. Alexander had served as the Senior Vice President, General Counsel and Corporate Secretary of PAREXEL International Corp. since September 2003. From June 2001 to September 2003, Ms. Alexander served as General Counsel of IONA Technologies. From January 1995 to May 2001, Ms. Alexander served as Counsel at Cabot Corp. Prior to that, Ms. Alexander was a partner of the law firms of Hinckley, Allen & Snyder and Fine & Ambrogne.
Paul J. Clancy is our Executive Vice President and Chief Financial Officer and has served in these positions since August 2007. Mr. Clancy has also served as Senior Vice President of Finance and Vice President of Business Planning at Biogen Idec. Prior to the merger, Mr. Clancy had served as Vice President of Portfolio Management at Biogen Inc. since 2003. He joined the company in 2001 as Vice President, US Marketing. Before joining Biogen, Mr. Clancy spent 13 years at PepsiCo, serving in a range of financial and general management positions including most recently Vice President and General Manager of their Great West Business Unit.
John G. Cox is our Executive Vice President of Pharmaceutical Operations & Technology and has served in this position since June 2010. Mr. Cox has also served as Senior Vice President of Technical Operations, Senior Vice President of Global Manufacturing, Vice President of Manufacturing & General Manager of Biogen Idec’s operations in Research Triangle Park, North Carolina, and Director of Manufacturing. Mr. Cox joined the company in 2003 as Director of Manufacturing Sciences. Before joining Biogen Idec from 2000 to 2003, Mr. Cox held a number of senior operational roles at Diosynth where he worked in technology transfer, validation and purification. Prior to that, Mr. Cox focused on the same areas at Wyeth Corporation from 1993 to 2000.
Kenneth DiPietro is our Executive Vice President of Human Resources and has served in this position since January 2012. Mr. Di Pietro joined Biogen Idec from Lenovo Group, where he served as Senior Vice President, Human Resources. From 2003 to 2005, he served as Corporate Vice President, Human Resources at Microsoft Corporation. From 1999 to 2002, Mr. Di Pietro worked as Vice President, Human Resources at Dell Inc. Prior to that, he spent 17 years at PepsiCo, serving in a range of human resource and general management positions. Mr. Di Pietro received his B.S. in Labor Relations from Cornell University.
Steven H. Holtzman is our Executive Vice President, Corporate Development and has served in this position since January 2011. Mr. Holtzman joined Biogen Idec from Infinity Pharmaceuticals Inc., where he was a founder and, most recently, Executive Chair of the Board of Directors. From 1994 until 2001, Mr. Holtzman was Chief Business Officer at Millennium Pharmaceuticals Inc., now a subsidiary of Takeda. He was also the co-founder, member of the Board of Directors and Executive Vice President of DNX Corporation, formerly Embryogen, Inc. From 1996 to 2001, Mr. Holtzman served as presidential appointee to the national Bioethics Advisory Commission. Mr. Holtzman received his B.A. in Philosophy from Michigan State University and his B.Phil. degree in Philosophy from Corpus Christi College and Oxford University, which he attended as a Rhodes Scholar.
Tony Kingsley is our Executive Vice President of Global Commercial Operations and has served in this position since November 2011. Mr. Kingsley also served as Senior Vice President of U.S. Commercial Operations. Prior to joining Biogen Idec in January 2010, Mr. Kingsley was Senior Vice President and General Manager of the Gynecological Surgical Products business at Hologic, Inc., where he ran Sales & Marketing, R&D and Operations. He also served as Division President, Diagnostic Products for Cytyc Corp., where he directed U.S. commercial operations and had global responsibility for manufacturing and supply chain, field and technical service, regulatory and quality, and R&D. From 1991-2006, Mr. Kingsley was a Partner at McKinsey and Company, Inc., focusing on the pharmaceuticals, biotech and medical device industries. Mr. Kingsley holds a B.A. degree in Government from Dartmouth College and an M.B.A. from Harvard Graduate School of Business Administration.
Ray Pawlicki is our Senior Vice President and Chief Information Officer and has served in this position since September 2008. Prior to that, Ray was the Chief Information Officer of Novartis Pharmaceuticals based in Basel, Switzerland where he focused on improving IT’s partnership with business and lowering costs. From 2000 to 2004, prior to relocating to Switzerland, Ray was Vice President and Chief Information Officer for the U.S. affiliate of Novartis Pharmaceuticals. Before the roles at Novartis, Ray held several positions of increasing responsibility with PepsiCo and CitiGroup where he focused on innovative uses of technology to help drive the business. Mr. Pawlicki received his B.S. in Computer Science from Montclair State University.
Douglas E. Williams, Ph.D., is our Executive Vice President, Research and Development and has served in this position since January 2011. He joined Biogen Idec from ZymoGenetics Inc., where he was most recently CEO and member of the Board of Directors. Previously, he held leadership positions within the biotechnology industry, including Chief Scientific Officer and Executive Vice President of Research and Development at Seattle Genetics Inc., and Senior Vice President and Washington Site Leader at Amgen Inc. Dr. Williams also served in a series of scientific and senior leadership positions over a decade at Immunex Corp., including Executive Vice President and Chief Technology Officer, Senior Vice President of Discovery Research and Vice President of Research and Development. Prior to joining Immunex, Dr. Williams served on the faculty of the Indiana University School of Medicine and the Department of Laboratory Medicine at the Roswell Park Memorial Institute in Buffalo, New York.